ダウンロード数: 297

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s13014-017-0765-4.pdf2.34 MBAdobe PDF見る/開く
タイトル: Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma
著者: Futamura, Gen
Kawabata, Shinji
Nonoguchi, Naosuke
Hiramatsu, Ryo
Toho, Taichiro
Tanaka, Hiroki  kyouindb  KAKEN_id
Masunaga, Shin-Ichiro  KAKEN_id
Hattori, Yoshihide
Kirihata, Mitsunori
Ono, Koji
Kuroiwa, Toshihiko
Miyatake, Shin-Ichi
著者名の別形: 田中, 浩基
増永, 慎一郎
小野, 公二
キーワード: Boron neutron capture therapy
F98 rat glioma model
ACBC-BSH
発行日: 23-Jan-2017
出版者: Springer Nature
誌名: Radiation Oncology
巻: 12
論文番号: 26
抄録: [Background]Boron neutron capture therapy (BNCT) is a unique particle radiation therapy based on the nuclear capture reactions in boron-10. We developed a novel boron-10 containing sodium borocaptate (BSH) derivative, 1-amino-3-fluorocyclobutane-1-carboxylic acid (ACBC)-BSH. ACBC is a tumor selective synthetic amino acid. The purpose of this study was to assess the biodistribution of ACBC-BSH and its therapeutic efficacy following Boron Neutron Capture Therapy (BNCT) of the F98 rat glioma. [Methods]We evaluated the biodistribution of three boron-10 compounds, ACBC-BSH, BSH and boronophenylalanine (BPA), in vitro and in vivo, following intravenous (i.v.) administration and intratumoral (i.t.) convection-enhanced delivery (CED) in F98 rat glioma bearing rats. For BNCT studies, rats were stratified into five groups: untreated controls, neutron-irradiation controls, BNCT with BPA/i.v., BNCT with ACBC-BSH/CED, and BNCT concomitantly using BPA/i.v. and ACBC-BSH/CED. [Results]In vitro, ACBC-BSH attained higher cellular uptake F98 rat glioma cells compared with BSH. In vivo biodistribution studies following i.v. administration and i.t. CED of ACBC-BSH attained significantly higher boron concentrations than that of BSH, but much lower than that of BPA. However, following convection enhanced delivery (CED), ACBC-BSH attained significantly higher tumor concentrations than BPA. The i.t. boron-10 concentrations were almost equal between the ACBC-BSH/CED group and BPA/i.v. group of rats. The tumor/brain boron-10 concentration ratio was higher with ACBC-BSH/CED than that of BPA/i.v. group. Based on these data, BNCT studies were carried out in F98 glioma bearing rats using BPA/i.v. and ACBC-BSH/CED as the delivery agents. The corresponding mean survival times were 37.4 ± 2.6d and 44.3 ± 8.0d, respectively, and although modest, these differences were statistically significant. [Conclusions]Our findings suggest that further studies are warranted to evaluate ACBC-BSH/CED as a boron delivery agent.
著作権等: © The Author(s). 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
URI: http://hdl.handle.net/2433/218714
DOI(出版社版): 10.1186/s13014-017-0765-4
PubMed ID: 28114947
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。